A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Moderate to Severe Systemic Lupus Erythematosus - Trial NCT06413511
Access comprehensive clinical trial information for NCT06413511 through Pure Global AI's free database. This Phase 1 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 1
May 29, 2024
Nov 24, 2025
Primary Outcome
Number of participants with adverse events (AEs) and serious adverse events (SAEs),Number of participants with clinically important findings in vital signs,Number of participants with clinically important findings in electrocardiogram,Number of participants with clinically important findings in echocardiogram,Number of participants with clinically important findings in haematology,Number of participants with clinically important findings in clinical chemistry,Number of participants with clinically important findings in urinalysis parameters,Number of participants with clinically important findings in corneal toxicity
Summary
The goal of this clinical trial is to assess the safety and tolerability profile of
 belantamab. The study will also assess how the levels of belantamab change over time and
 body's reaction to it in participants with moderate to severe systemic lupus erythematosus
 (SLE).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06413511
Non-Device Trial